Lee Pharma Profile
Key Indicators
- Authorised Capital ₹ 7.65 Cr
- Paid Up Capital ₹ 1.69 Cr
- Company Age 27 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 550.39 Cr
- Satisfied Charges ₹ 493.66 Cr
- Revenue Growth 26.82%
- Profit Growth -1.52%
- Ebitda 35.19%
- Net Worth 21.50%
- Total Assets 28.95%
About Lee Pharma
Lee Pharma Limited (LPL) is a leading Public Limited Indian Non-Government Company incorporated in India on 06 October 1997 and has a history of 27 years and four months. Its registered office is in Hyderabad, Telangana, India.
The Corporate was formerly known as Lee Pharma Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 7.65 Cr and a paid-up capital of Rs 1.69 Cr.
The company currently has active open charges totaling ₹550.39 Cr. The company has closed loans amounting to ₹493.66 Cr, as per Ministry of Corporate Affairs (MCA) records.
Venkata Alla, Dr Tatineni, Anil Jain, and Five other members serve as directors at the Company.
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24230TG1997PLC028095
- Company No.
028095
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
06 Oct 1997
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
What products or services does Lee Pharma Limited offer?
Lee Pharma Limited offers a wide range of products and services, including Pharma Ingredients & Raw Materials, Antipyretic and Analgesic API, Pharmaceutical Pellets, Anti Infective Drugs & Medicines, HIV Drugs, Antibacterial Drugs, Cardiovascular Drugs & Medication, Antianginal Drugs, API (Active Pharmaceutical Ingredients).
Who are the key members and board of directors at Lee Pharma?
Executive Team (1)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Venkata Alla ![]() | Managing Director | 06-Oct-1997 | Current |
Board Members (7)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Vijaykumar Agrawal ![]() | Director | 27-Sep-2007 | Current |
Dr Tatineni ![]() | Director | 22-Apr-1999 | Current |
Anil Jain ![]() | Nominee Director | 29-Jul-2023 | Current |
Ramaseshappa Panchangam ![]() | Director | 24-Oct-2024 | Current |
Santosh Busani ![]() | Director | 30-Sep-2021 | Current |
Raghumitra Alla ![]() | Whole-Time Director | 04-May-2006 | Current |
Financial Performance of Lee Pharma.
Lee Pharma Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 26.82% increase. The company also saw a slight decrease in profitability, with a 1.52% decrease in profit. The company's net worth Soared by an impressive increase of 21.5%.


- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Lee Pharma?
In 2023, Lee Pharma had a promoter holding of 57.44% and a public holding of 42.56%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Charges (Loans)
₹550.39 Cr
₹493.66 Cr
Charges Breakdown by Lending Institutions
- Sbicap Trustee Company Limited : 425.93 Cr
- Others : 90.00 Cr
- Hdfc Bank Limited : 21.96 Cr
- Axis Bank Limited : 12.50 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
17 May 2024 | Axis Bank Limited | ₹12.50 Cr | Open |
02 Jan 2024 | Others | ₹25.00 Cr | Open |
19 May 2023 | Others | ₹30.00 Cr | Open |
19 May 2023 | Others | ₹5.00 Cr | Open |
23 Mar 2023 | Hdfc Bank Limited | ₹21.96 Cr | Open |
How Many Employees Work at Lee Pharma?
Lee Pharma has a workforce of 1221 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Deals i

Gain comprehensive insights into the Deals and Valuation data of Lee Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Lee Pharma's trajectory.
Rating

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.